Millington Financial Advisors LLC Purchases Shares of 20,000 Grace Therapeutics, Inc. $GRCE

Millington Financial Advisors LLC bought a new stake in shares of Grace Therapeutics, Inc. (NASDAQ:GRCE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $59,000. Millington Financial Advisors LLC owned approximately 0.14% of Grace Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC bought a new position in Grace Therapeutics during the second quarter worth $144,000. Stonepine Capital Management LLC bought a new stake in shares of Grace Therapeutics during the first quarter valued at about $666,000. ADAR1 Capital Management LLC bought a new position in shares of Grace Therapeutics in the first quarter valued at approximately $783,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Grace Therapeutics during the 1st quarter valued at $2,686,000. 6.08% of the stock is currently owned by institutional investors.

Grace Therapeutics Price Performance

Shares of GRCE stock opened at $3.18 on Friday. The stock has a fifty day moving average price of $3.09 and a 200 day moving average price of $3.07. The stock has a market cap of $49.21 million, a P/E ratio of -3.70 and a beta of 0.99. Grace Therapeutics, Inc. has a one year low of $1.75 and a one year high of $4.97.

Grace Therapeutics (NASDAQ:GRCE) last released its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). Equities research analysts anticipate that Grace Therapeutics, Inc. will post -1.06 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GRCE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Grace Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Grace Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.00.

Grace Therapeutics Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.